CC
MCRB icon

Centiva Capital’s Seres Therapeutics MCRB Stock Holding History

Centiva Capital’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-9,390
Closed -$136K – 2428
2024
Q2 		$136K Buy
+9,390
New +$157K ﹤0.01% 1794
2022
Q3 		– Sell
-732
Closed -$50K – 1689
2022
Q2 		$50K Buy
+732
New +$63.1K ﹤0.01% 1470

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vontobel Holding
Vontobel Holding Zurich, Switzerland $31.4B AUM 31.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return

Centiva Capital's MCRB Position: Q3 2024 in Review

Centiva Capital sold out of Seres Therapeutics (MCRB) in Q3 2024, closing a stake of 9,390 shares — an estimated $136K sold.

Centiva Capital first reported a position in MCRB in Q2 2022 and held it in 2 quarters. The position peaked at $136K in Q2 2024. 77 funds tracked by Wall St. Rank hold MCRB as of Q3 2024.

  • Centiva Capital reported no remaining Seres Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Centiva Capital sold 9,390 Seres Therapeutics shares in Q3 2024, an estimated $136K.
  • Centiva Capital first reported a position in Seres Therapeutics in Q2 2022 and held it in 2 quarters.
  • Centiva Capital's Seres Therapeutics position peaked at $136K in Q2 2024.
  • 77 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2024.

Based on Centiva Capital's 13F filing for Q3 2024, filed 14 Nov 2024.